<p>|Recommendation|Level of evidence (evidence [refs.] reviewed)†|
|---|---|
|In adult patients with active PsA despite treatment with an OSM,| |
|1. Switch to a TNFi biologic over a different OSM (PICO 23)|Moderate (62–66, 69–86)|